posted on 2016-12-22, 00:00authored byStephen S. Scully, Zachary J. Minden, Ratul Mukerji, Elizaveta Andrianova, James Kaberna, Scott Lentini, Carlos Tassa, Zhaolin Wang, Susan Low, Kevin A. McDonnell
Several
monoclonal antibodies and inhibitors targeting CD38, an
ectoenzyme overexpressed on malignant plasma cells, have previously
been discovered. Herein, we expand structure–activity relationships
of reported small-molecule thiazoloquinolinones and show that several
4-cyclohexylamino analogues have potent binding affinity for CD38
using surface plasmon resonance. Moreover, active amine analogues
could be acylated and functionalized with alkyne and fluorescein groups.
Fluorescein analogue 21 bound selectively to CD38 overexpressing
cells, demonstrating the potential utility of thiazoloquinolinones
as small-molecule conjugates for the delivery of therapeutic and imaging
agents.